Since 2017, the U.S. Food and Drug Administration has approved six CAR T-cell treatments for blood cancers, including lymphomas, some forms of leukemia, and multiple myeloma. Touted as one of the most exciting medical advances of the past decade, CAR T-cell therapies provide hope for patients facing relapse or unresponsive cancer, where conventional treatments like chemotherapy, surgery, or radiation have fallen short. Due to its success, there has been an uptick in sponsors launching clinical trials for the targeted form of therapy.
According to reports, there are over 1,000 CAR T-cell trials registered with the FDA, with 627 currently active, and the number of trial starts has grown 38.7% year over year. However, many of these trials are still in Phase 1, meaning that patients whose cancer isn’t responding fast enough or who have already relapsed can’t afford delays. Explore how innovative technologies are empowering advancements in CAR T-cell therapy, enhancing patient outcomes, and streamlining trial processes.